May 13, 2015
Novocure to Present New Clinical and Preclinical Data on Tumor Treating Fields at the American Society of Clinical Oncology Annual Meeting 2015
Presentation by Roger Stupp, MD will be the first report on the full 700 patient population that enrolled to the EF-14 trial in newly diagnosed glioblastoma 2015 ASCO Annual Meeting May 13, 2015 05:00 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage… Read More
learn more
May 11, 2015
FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma
PMA Supplement application for Tumor Treating Fields in combination with temozolomide chemotherapy for newly diagnosed glioblastoma accepted for filing and review May 11, 2015 10:54 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that its Premarket Approval (PMA)… Read More
learn more
May 11, 2015
NCCN Guidelines Recommend Tumor Treating Fields as a Standard Treatment Option for Recurrent Glioblastoma
Optune, a Tumor Treating Fields delivery system, provides a non-invasive, low-toxicity, home-use treatment for recurrent glioblastoma, the most common malignant primary brain cancer May 11, 2015 12:18 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that Optune has… Read More
learn more
May 5, 2015
Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Address Challenges in the Glioblastoma Community
Tune-In to GBM initiative will culminate in first GBM Hackathon event to find innovative solutions for patients and caregivers May 05, 2015 08:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that it is sponsoring its Tune-In to GBM… Read More
learn more
April 10, 2015
New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015
AACR Annual Meeting 2015 April 10, 2015 08:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that four preclinical abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia to be held April 18-22,… Read More
learn more
April 9, 2015
Intersect ENT Appoints Kieran Gallahue and Tony Vernon to Board of Directors
April 09, 2015 07:35 PM Eastern Daylight Time MENLO PARK, Calif.–(BUSINESS WIRE)–Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the appointment of Kieran T. Gallahue and W. Anthony Vernon to the company’s… Read More
learn more
March 30, 2015
Novocure Announces Japanese Approval of Optune (the NovoTTF-100A System) for Treatment of Recurrent Glioblastoma
Approval provides Japanese recurrent glioblastoma patients with a new, effective and safe treatment option Approval allows for rapid, direct commercial market access in Japan, the world’s second largest medical device market Optune™ (formerly NovoTTF™-100A System) (Photo: Business Wire) March 30, 2015 08:00 AM… Read More
learn more
February 23, 2015
Novocure Enrolls the First Patient in its Phase II STELLAR Trial of Tumor Treating Fields Together with Pemetrexed and Cisplatin or Carboplatin for the Treatment of Malignant Mesothelioma
STELLAR will test the efficacy and safety of Tumor Treating Fields applied to the thorax together with standard of care chemotherapy for treatment of mesothelioma February 23, 2015 08:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that… Read More
learn more
January 12, 2015
Novocure Announces the Completion of Enrollment of its PANOVA Trial of Tumor Treating Fields Plus Gemcitabine for Treatment of Pancreatic Cancer
The PANOVA trial will now be expanded to treat an additional twenty advanced pancreatic cancer patients with concomitant TTFields, gemcitabine and nab-paclitaxel January 12, 2015 10:19 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the last patient… Read More
learn more
January 8, 2015
Novocure Announces $100 Million Term Loan Agreement with Pharmakon Advisors
January 08, 2015 08:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that it has entered into a term loan agreement with an investment fund managed by Pharmakon Advisors LP. The agreement provides Novocure with up to $100 million of available… Read More
learn more
